Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-07-07

FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Actavis Pharma, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Buprenorphine and Naloxone (Actavis Pharma, Inc.), marking the approval of a generic product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine and naloxone (BUPRENORPHINE AND NALOXONE)

Snippet

SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE AND NALOXONE)